R&D channel feed – Endpoints News

R&D channel feed

Eli Lilly conducts an autopsy of an Alzheimer’s megaflop

9 years ago

Biogen spells out remarkable efficacy data in Alzheimer's for aducanumab, but safety threat persists

9 years ago

Horizon Pharma folds its cards on Friedreich’s Ataxia after Actimmune flunks PhIII

9 years ago

Voyager shares spike on an early glimpse of promise for Parkinson’s gene therapy

9 years ago

J&J is forced to suspend recruitment in PhI diabetes study, raising questions about another Hanmi drug

9 years ago

AbbVie’s PARP inhibitor flounders in PhII as rivals surge ahead in late-stage drive

9 years ago

With new name, new CEO, Cascadian now rolls out a new pivotal plan for lead cancer drug

9 years ago

The FDA just signed off on a Formula 1 pivotal track for Sage's postpartum depression drug

9 years ago

In a rare blockbuster performance for AstraZeneca, Tagrisso comes through on lung cancer PhIII

9 years ago

Juno gets some badly needed relief after a glimpse of upbeat early data on JCAR017

9 years ago

Cerecor blasted as its second clinical roll of the dice in days comes up snake eyes

9 years ago

Rattled by immune responses, Spark will pay $30M-plus to get Selecta’s help in ending threat

9 years ago

ReNeuron’s stem cell treatment fails a small stroke study, but the biotech says it’s ready for pivotal

9 years ago

Kite adds promising leukemia responses in small CAR-T studies, then fires the starting gun on its rolling submission

9 years ago

What makes a PhII drug worth up to $665M? Researchers spell it out for Novartis

9 years ago

#ASH16: Pfizer offers a thumbs-up on OS data from PhII blood cancer study of glasdegib

9 years ago

In wake of a CAR-T restructuring, Novartis says it’s ready to hunt a pioneering OK for lead program

9 years ago

Lethally severe neurotoxicity continues to haunt Juno’s CAR-T pipeline

9 years ago

Booming CRISPR pioneer Intellia looks to double staff with new digs

9 years ago

Cutting back in the UK, Takeda spins out its top neuroscience team into a transatlantic biotech

9 years ago

Round 2 in Boehringer's US reorganization will claim another 244 jobs, including small molecule group

9 years ago

A disruptive billionaire with a yen for innovation herds top researchers into a neoantigen cancer coalition

9 years ago

Bluebird, Celgene jump off to a promising start in the marathon race to develop a CAR-T for multiple myeloma

9 years ago

In Lechleiter's final days, Eli Lilly flags upcoming job cuts in the wake of a PhIII implosion

9 years ago

First page Previous page 310 311 312313314 315 316 Next page Last page